
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biotech company with a strong focus on developing therapies for serious diseases associated with dysregulated immune responses. Their lead product candidate, GRI-0621, has shown positive results in treating idiopathic pulmonary fibrosis (IPF) and has potential for use in other autoimmune disorders. Recent fiscal Q1 results were in line with expectations, indicating solid financial management. However, success in clinical trials and regulatory approvals are key factors in future growth and share price.
Bears say
GRI Bio is a clinical-stage biopharmaceutical company with a focus on developing therapies for diseases related to immune response. Despite positive top-line data for their lead drug GRI-0621, concerns surrounding the long development and commercialization process and high risks associated with clinical trials and commercial failures, lead to an adjusted EPS estimate and a lower price target. However, the company's current valuation presents an attractive opportunity for potential investors looking to balance the high risks with the potential for significant upside.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares